These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 16234364)

  • 41. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
    Castro JE; Prada CE; Loria O; Kamal A; Chen L; Burrows FJ; Kipps TJ
    Blood; 2005 Oct; 106(7):2506-12. PubMed ID: 15972449
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
    Richardson PG; Mitsiades CS; Laubach JP; Lonial S; Chanan-Khan AA; Anderson KC
    Br J Haematol; 2011 Feb; 152(4):367-79. PubMed ID: 21219297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
    Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
    Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
    Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
    Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis.
    Poulaki V; Iliaki E; Mitsiades N; Mitsiades CS; Paulus YN; Bula DV; Gragoudas ES; Miller JW
    FASEB J; 2007 Jul; 21(9):2113-23. PubMed ID: 17400913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
    Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
    Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
    Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
    Neznanov N; Komarov AP; Neznanova L; Stanhope-Baker P; Gudkov AV
    Oncotarget; 2011 Mar; 2(3):209-21. PubMed ID: 21444945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.
    Wang SX; Ju HQ; Liu KS; Zhang JX; Wang X; Xiang YF; Wang R; Liu JY; Liu QY; Xia M; Xing GW; Liu Z; Wang YF
    Biosci Biotechnol Biochem; 2011; 75(8):1540-5. PubMed ID: 21821931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
    Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P
    Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
    Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
    Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
    Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y; Rahmani M; Pei XY; Dent P; Grant S
    Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.